Skip to content
An Initiative of AVAC In partnership with Access Bridge
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 121 - 130 of 187

Selected Filters:
7 July 2022

Microbicide Trials Network-043 – B-PROTECTED Study

Microbicide Trials Network-043, or B-PROTECTED, is a Phase IIIb open-label study that evaluated the safety and acceptability of the monthly dapivirine ring and daily oral PrEP in women who are breastfeeding, a time of heightened vulnerability for acquiring HIV.

Research

External Link
7 July 2022

Use of the Dapivirine vaginal ring and effect on cervical cytology abnormalities

This study aims to determine if the dapivirine vaginal ring and the ring device alone (flexible silicone matrix polymer) was associated with the development of cervical cytology abnormalities.

Research, Service Delivery

External Link
7 July 2022

Vaginal Ring Acceptability and Related Preferences among Women in Low- and Middle-income Countries: A systematic review and narrative synthesis

The vaginal ring (VR) is a female-initiated drug-delivery platform used for different indications, including HIV pre-exposure prophylaxis (PrEP). This article outlines a systematic review of VR acceptability, values and preferences among women in low- and middle-income countries (LMIC) to inform further investment and/or guidance on VR use for HIV prevention.

Research

External Link
7 July 2022

HOPE Protocol Team Meeting Lessons Learned from PrEP Rollout for the Dapivirine Ring

This presentation outlines lessons from oral PrEP demonstration projects that could be applied to the rollout of the dapivirine vaginal ring as well as plans for ring introduction.

Research

Document
7 July 2022

The Years Ahead in Biomedical HIV Prevention Research

This graphic shows the updated status of large-scale prevention trials through 2024.

Community/Advocacy

External Link
7 July 2022

Pre-Exposure Prophylaxis: An introductory factsheet

This introductory 2-page document defines PrEP, reviews the scientific evidence to date, and outlines key research, regulatory and advocacy issues going forward. This factsheet is part of a series on emerging HIV prevention strategies.

Community/Advocacy

External Link
7 July 2022

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness

A vaginal ring containing dapivirine is effective for HIV prevention as pre-exposure prophylaxis (PrEP). The authors of this article evaluated the potential epidemiological impact and cost-effectiveness of dapivirine vaginal ring PrEP among 22- to 45-year-old women in KwaZulu-Natal, South Africa.

Research, Service Delivery

External Link
7 July 2022

Ring Backgrounder

What is the dapivirine ring? How does it work? Is it safe to use? These are all questions that this Dapivirine Ring backgrounder by the International Partnership for Microbicides (IPM) answers.

Community/Advocacy

External Link
7 July 2022

Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach

These consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring bring together existing and new clinical and programmatic recommendations across different ages, populations and settings, bringing together all relevant WHO guidance on HIV produced since 2016. It serves as an update to the previous edition of the consolidated guidelines on HIV.

Normative Guidance/Policies, Service Delivery

External Link
7 July 2022

WHO recommends the Dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection

This article announces the WHO's recommendation that the dapivirine vaginal ring may be offered as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches.

Community/Advocacy, Normative Guidance/Policies

External Link